At the J.P. Morgan Healthcare Conference in San Francisco, the AI drug discovery pitch is familiar: shrink timelines, automate bottlenecks, take a process that spans a decade-plus and billions of dollars and compress it. For years, the industry has treated speed and cost as the headline metrics. The numbers, however, still point in the wrong…
